SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model

被引：326

作者：

Qiao, Jingxin ^{[1
]}

Li, Yue-Shan ^{[1
]}

Zeng, Rui ^{[1
]}

Liu, Feng-Liang ^{[2
,3
]}

Luo, Rong-Hua ^{[2
,3
]}

Huang, Chong ^{[1
]}

Wang, Yi-Fei ^{[4
]}

Zhang, Jie ^{[1
]}

Quan, Baoxue ^{[1
]}

Shen, Chenjian ^{[1
]}

Mao, Xin ^{[1
]}

Liu, Xinlei ^{[1
]}

Sun, Weining ^{[1
]}

Yang, Wei ^{[1
]}

Ni, Xincheng ^{[1
]}

Wang, Kai ^{[1
]}

Xu, Ling ^{[2
,3
]}

Duan, Zi-Lei ^{[2
,3
]}

Zou, Qing-Cui ^{[3
]}

Zhang, Hai-Lin ^{[3
,5
]}

Qu, Wang ^{[3
]}

Long, Yang-Hao-Peng ^{[3
]}

Li, Ming-Hua ^{[3
]}

Yang, Rui-Cheng ^{[1
]}

Liu, Xiaolong ^{[1
]}

You, Jing ^{[1
]}

Zhou, Yangli ^{[1
]}

Yao, Rui ^{[1
]}

Li, Wen-Pei ^{[1
]}

Liu, Jing-Ming ^{[1
]}

Chen, Pei ^{[4
]}

Liu, Yang ^{[1
]}

Lin, Gui-Feng ^{[1
]}

Yang, Xin ^{[1
]}

Zou, Jun ^{[1
]}

Li, Linli ^{[4
]}

Hu, Yiguo ^{[1
]}

Lu, Guang-Wen ^{[1
]}

Li, Wei-Min ^{[1
]}

Wei, Yu-Quan ^{[1
]}

Zheng, Yong-Tang ^{[2
,3
]}

Lei, Jian ^{[1
,6
]}

Yang, Shengyong ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China

[2] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China

[3] Chinese Acad Sci, Ctr Biosafety Megasci, Kunming Inst Zool, Kunming Natl High Level Biosafety Res Ctr Nonhuma, Kunming 650107, Yunnan, Peoples R China

[4] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China

[5] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China

[6] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China

来源：

SCIENCE | 2021年 / 371卷 / 6536期

基金：

国家重点研发计划; 中国国家自然科学基金;

关键词：

3CL PROTEASE INHIBITORS; SARS; DISCOVERY; DESIGN;

D O I：

10.1126/science.abf1611

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M-pro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M-pro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M-pro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M-pro in complex with MI-23, one of themost potent compounds, revealed its interactionmode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment withMI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.

引用

页码：1374 / +

页数：89

共 45 条

[1] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs
Anand, K
Ziebuhr, J
Wadhwani, P
Mesters, JR
Hilgenfeld, R
[J]. SCIENCE, 2003, 300 (5626) : 1763 - 1767
[2] Boras B., 2020, 293498 BIORXIV
[3] Boras Britton, 2021, bioRxiv, DOI 10.1101/2020.09.12.293498
[4] Bricogne G, 2017, BUSTER version 2.10.4
[5] Cannalire R., 2020, **DROPPED REF**
[6] MolProbity: all-atom structure validation for macromolecular crystallography
Chen, Vincent B.
Arendall, W. Bryan, III
Headd, Jeffrey J.
Keedy, Daniel A.
Immormino, Robert M.
Kapral, Gary J.
Murray, Laura W.
Richardson, Jane S.
Richardson, David C.
[J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2010, 66 : 12 - 21
[7] Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Yu
Liu, Qianyun
Guo, Deyin
[J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (04) : 418 - 423
[8] Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Dai, Wenhao
Zhang, Bing
Jiang, Xia-Ming
Su, Haixia
Li, Jian
Zhao, Yao
Xie, Xiong
Jin, Zhenming
Peng, Jingjing
Liu, Fengjiang
Li, Chunpu
Li, You
Bai, Fang
Wang, Haofeng
Cheng, Xi
Cen, Xiaobo
Hu, Shulei
Yang, Xiuna
Wang, Jiang
Liu, Xiang
Xiao, Gengfu
Jiang, Hualiang
Rao, Zihe
Zhang, Lei-Ke
Xu, Yechun
Yang, Haitao
Liu, Hong
[J]. SCIENCE, 2020, 368 (6497) : 1331 - +
[9] Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors.: 4.: Incorporation of P1 lactam moieties as L-glutamine replacements
Dragovich, PS
Prins, TJ
Zhou, R
Webber, SE
Marakovits, JT
Fuhrman, SA
Patick, AK
Matthews, DA
Lee, CA
Ford, CE
Burke, BJ
Rejto, PA
Hendrickson, TF
Tuntland, T
Brown, EL
Meador, JW
Ferre, RA
Harr, JEV
Kosa, MB
Worland, ST
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) : 1213 - 1224
[10] Features and development of Coot
Emsley, P.
Lohkamp, B.
Scott, W. G.
Cowtan, K.
[J]. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2010, 66 : 486 - 501

← 1 2 3 4 5 →